Molecular Subtype
HER2-Positive Gastric Adenocarcinoma
CI-CAN-00007796Explore in graph →
15 active trials
- NCIt
- C227256
Loading cancer entity…
Molecular Subtype
CI-CAN-00007796Explore in graph →
Clinical trials
43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer |
| unknown |
| Phase 1 |
| 28 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Mar 4, 2015 |
| clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2024source: clinicaltrials